The Asia Pacific gastrointestinal drugs market is expected to reach US$ 13,618.35 million by 2027 from US$ 8,868.44 million in 2019; it is estimated to grow at a CAGR of 5.6% from 2020 to 2027.
Rising prevalence of gastrointestinal (GI) diseases, and increase in development of biologics are the key factors driving the growth of gastrointestinal drugs. However, side effects associated with the drugs is the major factor hindering the market growth in Asia Pacific.Gastrointestinal (GI) disorders are the medical conditions related to the digestive system that affect the colon, small and large intestine, and rectum. The disorders include constipation, irritable bowel, ulcerative colitis, and peptic ulcer diseases. These disorders are characterized by various symptoms such as pain, bloating, diarrhoea, nausea, and vomiting. These disorders constitute a large proportion of outpatients and frequent hospital visits. A wide range of GI drugs is commercially available in the market for the treatment of various conditions. Additionally, rising investments in the development of biologics and the emergence of a biosimilar are expected to drive the growth of the market in the forecast period.
Growing prevalence of IBD can be ascribed to poor nutritional choices, including a high intake of ultra-processed foods and trans-fats. Several studies have highlighted the accelerated growth of gastrointestinal diseases in Asian populations during the past two decades. Both incidence and prevalence rates have shown a notable rise, with scientists pointing out that GI diseases are increasingly the cause of morbidity and mortality in Asian countries. In the World Cancer Research Fund’s annual ranking of the top 20 countries with the highest incidence of stomach cancer, Korea (42 per 100,000), Japan (30 per 100,000), and China (23 per 100,000) ranked as 1st, 3rd, and 5th respectively.
Gastrointestinal (GI) diseases, in particular, are becoming common and have been linked to changing environmental factors brought on by improved sanitation, industrialization, changes in diet, and the increased use of antibiotics. Common GI diseases include ulcerative colitis (UC), colorectal cancer, gastroesophageal reflux disease, inflammatory bowel disease (IBD), and Crohn’s disease (CD). Due to these factors, medical device companies in the GI space have been expanding their business operations in Asia. The incidence and prevalence of many GI disorders are highest amongst the very young and the elderly. As the population ages, the disease burden is expected to grow. The incidence and prevalence of IBD have increased in the last few decades. As per the International Foundation for Gastrointestinal Disorders, Inc., IBD is the most common functional GI disorder with a prevalence rate of 10–15%. Also, it is one of the most common conditions for a visit to a doctor.
Countries in the Asia Pacific are facing challenges due to increasing incidences of COVID-19. The outbreak has severely affected the tourism industry and imposed supply chain disruptions; moreover, low-income countries face additional challenges due to the shortage of healthcare infrastructure. Restrictive measures have been put forth in South Korea, Malaysia, Singapore, the Philippines, and India to prevent disease transmission. All these factors will impact gastrointestinal drug market for short period of time due to restrictions on supply chain as well as limited manufacturing capabilities. However, in long run the market has strong potential to boost the growth rate as Asia Pacific is most populated region in the world and one of the strong consumers of over the counter generic medications including gastrointestinal disorder drug products.
Rest of Asia Pacific Gastrointestinal drugs Market, Revenue and Forecast to 2027 (US$ Mn)
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
ASIA PACIFIC GASTROINTESTINAL DRUGS MARKET SEGMENTATION
By Drug Class
- Acid Neutralizers
- Antidiarrheal and Laxatives
- Anti-Inflammatory Drugs
- Antiemetic and Antinauseants
- Biologics
- Others
By Route of Administration
- Oral
- Parenteral
By Application
- Inflammatory Ulcerative Colitis
- Crohn's Disease
- Irritable Bowel Syndrome
- Gastroenteritis
- Celiac Disease
- Others
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Country
- Japan
- China
- India
- South Korea
- Australia
- Rest of APAC
Company Profiles
- Johnson and Johnson Services, Inc.
- GlaxoSmithKline plc
- Celltrion Healthcare Co., Ltd.
- AstraZeneca
- Takeda Pharmaceutical Company Limited
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Drug Class, Route of Administration, Application, and Distribution Channel, and Country
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Australia, China, Japan, South Korea
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Asia Pacific Gastrointestinal Drugs Market – By Drug Class
1.3.2 Asia Pacific Gastrointestinal Drugs Market – By Route of Administration
1.3.3 Asia Pacific Gastrointestinal Drugs Market – By Application
1.3.4 Asia Pacific Gastrointestinal drugs Market – By Distribution Channel
1.3.5 Asia Pacific Gastrointestinal drugs Market – By Country
2. Asia Pacific Gastrointestinal Drugs Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Gastrointestinal Drugs Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Gastrointestinal Drugs Market - Asia Pacific PEST Analysis
4.3 Expert Opinion
5. Asia Pacific Gastrointestinal Drugs Market - Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Rise in Prevalence of Gastrointestinal (GI) Diseases
5.1.2 Increase in Development of Biologics
5.2 Market Restraints
5.2.1 Low Awareness Associated with Gastrointestinal Disorders in Low-Income Economies
5.3 Market Opportunities
5.3.1 Increasing Investment in Research Activities and Growing Pipeline of GI Candidates
5.4 Future Trends
5.4.1 Emergence of Biosimilars
5.5 Impact Analysis
6. Gastrointestinal Drugs Market – Asia Pacific Analysis
6.1 Asia Pacific Gastrointestinal Drugs Market Revenue Forecasts and Analysis
7. Asia Pacific Gastrointestinal Drugs Market Analysis And Forecasts To 2027 – By Drug Class
7.1 Overview
7.2 Asia Pacific Gastrointestinal Drugs Market, By Drug Class 2019 & 2027 (%)
7.2.1 Asia Pacific Gastrointestinal drugs Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
7.3 Acid Neutralizers
7.3.1 Overview
7.3.2 Asia Pacific Acid Neutralizers Market Revenue and Forecast to 2027 (US$ Mn)
7.4 Antidiarrheal and Laxatives
7.4.1 Overview
7.4.2 Asia Pacific Antidiarrheal and Laxatives Market Revenue and Forecasts to 2027 (US$ Mn)
7.5 Anti-Inflammatory Drugs
7.5.1 Overview
7.5.2 Asia Pacific Anti-Inflammatory Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
7.6 Antiemetic and Antinauseants
7.6.1 Overview
7.6.2 Asia Pacific Antiemetic and Antinauseants Market Revenue and Forecast to 2027 (US$ Mn)
7.7 Biologics
7.7.1 Overview
7.7.2 Asia Pacific Biologics Market Revenue and Forecasts to 2027 (US$ Mn)
7.8 Others
7.8.1 Overview
7.8.2 Asia Pacific Others Market Revenue and Forecasts to 2027 (US$ Mn)
8. Asia Pacific Gastrointestinal Drugs Market Analysis – By Route of Administration
8.1 Overview
8.2 Asia Pacific Gastrointestinal Drugs Market, By Route of Administration 2019-2027 (%)
8.2.1 Asia Pacific Gastrointestinal Drugs Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)
8.3 Oral
8.3.1 Overview
8.3.2 Asia Pacific Oral Market Revenue and Forecasts to 2027 (US$ Mn)
8.4 Parenteral
8.4.1 Overview
8.4.2 Asia Pacific Parenteral Market Revenue and Forecasts to 2027 (US$ Mn)
9. Asia Pacific Gastrointestinal Drugs Market Analysis – By Application
9.1 Overview
9.2 Asia Pacific Gastrointestinal Drugs Market, By Application 2019-2027 (%)
9.2.1 Asia Pacific Gastrointestinal Drugs Market Revenue and Forecasts to 2027, By Application (US$ Mn)
9.3 Inflammatory Ulcerative Colitis
9.3.1 Overview
9.3.2 Asia Pacific Inflammatory Ulcerative Colitis Market Revenue and Forecasts to 2027 (US$ Mn)
9.4 Crohn's Disease
9.4.1 Overview
9.4.2 Asia Pacific Crohn's Disease Market Revenue and Forecasts to 2027 (US$ Mn)
9.5 Irritable Bowel Syndrome
9.5.1 Overview
9.5.2 Asia Pacific Irritable Bowel Syndrome Market Revenue and Forecasts to 2027 (US$ Mn)
9.6 Gastroenteritis
9.6.1 Overview
9.6.2 Asia Pacific Gastroenteritis Market Revenue and Forecasts to 2027 (US$ Mn)
9.7 Celiac Disease
9.7.1 Overview
9.7.2 Asia Pacific Celiac Disease Market Revenue and Forecasts to 2027 (US$ Mn)
9.8 Others
9.8.1 Overview
9.8.2 Asia Pacific Others Market Revenue and Forecasts to 2027 (US$ Mn)
10. Asia Pacific Gastrointestinal Drugs Market Analysis – By Distribution Channel
10.1 Overview
10.2 Asia Pacific Gastrointestinal Drugs Market, By Distribution Channel 2019-2027 (%)
10.2.1 Asia Pacific Gastrointestinal Drugs Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)
10.3 Hospital Pharmacies
10.3.1 Overview
10.3.2 Asia Pacific Hospital Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
10.4 Retail Pharmacies
10.4.1 Overview
10.4.2 Asia Pacific Retail Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
10.5 Online Pharmacies
10.5.1 Overview
10.5.2 Asia Pacific Online Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
11. Gastrointestinal Drugs Market Revenue and Forecasts To 2027 – Geographical Analysis
11.1 Asia Pacific Gastrointestinal Drugs Market Revenue and Forecasts To 2027
11.1.1 Overview
11.1.2 Asia Pacific: Gastrointestinal Drugs Market - Revenue and Forecast to 2027 (USD Million)
11.1.3 Asia Pacific: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.1.4 Asia Pacific: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.1.5 Asia Pacific: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.1.6 Asia Pacific: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.7 Asia Pacific: Gastrointestinal Drugs Market, by Country, 2018 & 2027 (%)
11.1.8 China: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.8.1 China: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.8.2 China: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.1.8.3 China: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.1.8.4 China: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.1.8.5 China: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.9 Japan: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.9.1 Japan: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.9.2 Japan: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.1.9.3 Japan: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.1.9.4 Japan: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.1.9.5 Japan: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.10 India: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.10.1 India: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.10.2 India: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.1.10.3 India: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.1.10.4 India: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.1.10.5 India: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.11 South Korea: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.11.1 South Korea: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.11.2 South Korea: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.1.11.3 South Korea: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.1.11.4 South Korea: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.1.11.5 South Korea: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.12 Australia: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.12.1 Australia: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.12.2 Australia: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.1.12.3 Australia: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.1.12.4 Australia: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.1.12.5 Australia: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.13 Rest of Asia-Pacific: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.13.1 Rest of Asia-Pacific: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.13.2 Rest of Asia-Pacific: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.1.13.3 Rest of Asia-Pacific: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.1.13.4 Rest of Asia-Pacific: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.1.13.5 Rest of Asia-Pacific: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
12. Impact of COVID-19 Pandemic on Asia Pacific Gastrointestinal Drugs Market
12.1 Asia Pacific: Impact Assessment of COVID-19 Pandemic
13. Company Profiles
13.1 Takeda Pharmaceutical Company Limited
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Celltrion Healthcare Co.,Ltd.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 GlaxoSmithKline plc.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 AstraZeneca
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Johnson and Johnson Services, Inc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
14. Appendix
14.1 Glossary of Terms
LIST OF TABLES
Table 1. Asia Pacific Gastrointestinal drugs Market Revenue and Forecasts To 2027, By Drug Class (US$ Mn)
Table 2. Asia Pacific Gastrointestinal Drugs Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)
Table 3. Asia Pacific Gastrointestinal Drugs Market Revenue and Forecasts To 2027, By Application (US$ Mn)
Table 4. Asia Pacific Gastrointestinal Drugs Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)
Table 5. Asia Pacific Gastrointestinal Drugs Market, by Drug Class– Revenue and Forecast to 2027 (USD Million)
Table 6. Asia Pacific Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 7. Asia Pacific Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 8. Asia Pacific Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 9. China Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 10. China Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 11. China Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 12. China Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 13. Japan Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 14. Japan Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 15. Japan Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 16. Japan Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 17. India Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 18. India Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 19. India Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 20. India Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 21. South Korea Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 22. South Korea Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 23. South Korea Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 24. South Korea Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 25. Australia Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 26. Australia Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 27. Australia Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 28. Australia Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 29. Rest of Asia-Pacific Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 30. Rest of Asia-Pacific Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 31. Rest of Asia-Pacific Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 32. Rest of Asia-Pacific Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 33. Glossary of Terms, Gastrointestinal Drugs Market
LIST OF FIGURES
Figure 1. Gastrointestinal Drugs Market Segmentation
Figure 2. Asia Pacific Gastrointestinal Drugs Market Overview
Figure 3. Acid Neutralizers Segment Held Largest Share of Product in Gastrointestinal Drugs Market
Figure 4. Japan is Expected to Show Remarkable Growth During the Forecast Period
Figure 5. Asia Pacific Gastrointestinal Drugs Market - Leading Country Markets (US$ Mn)
Figure 6. Gastrointestinal Drugs Market - Asia Pacific PEST Analysis
Figure 7. Gastrointestinal Drugs Market Impact Analysis of Drivers and Restraint
Figure 8. Asia Pacific Gastrointestinal Drugs market – Revenue Forecasts and Analysis – 2019- 2027
Figure 9. Asia Pacific Gastrointestinal Drugs Market, By Drug Class 2019 & 2027 (%)
Figure 10. Asia Pacific Acid Neutralizers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 11. Asia Pacific Antidiarrheal and Laxatives Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 12. Asia Pacific Anti-Inflammatory Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 13. Asia Pacific Antiemetic and Antinauseants Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 14. Asia Pacific Biologics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 15. Asia Pacific Anti-Inflammatory Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 16. Asia Pacific Gastrointestinal Drugs Market, by Route of Administration 2019 & 2027 (%)
Figure 17. Asia Pacific Oral Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 18. Asia Pacific Parenteral Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 19. Asia Pacific Gastrointestinal Drugs Market, by Application 2019 & 2027 (%)
Figure 20. Asia Pacific Inflammatory Ulcerative Colitis Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 21. Asia Pacific Crohn's Disease Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 22. Asia Pacific Irritable Bowel Syndrome Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 23. Asia Pacific Gastroenteritis Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 24. Asia Pacific Celiac Disease Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 25. Asia Pacific Others Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 26. Asia Pacific Gastrointestinal Drugs Market, by Distribution Channel 2019 & 2027 (%)
Figure 27. Asia Pacific Hospital Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 28. Asia Pacific Retail Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 29. Asia Pacific Online Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 30. Asia Pacific: Gastrointestinal Drugs Market, by Key Country – Revenue (2019) (USD Million)
Figure 31. Asia Pacific Gastrointestinal Drugs Market Revenue and Forecast to 2027 (USD Million)
Figure 32. China: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 33. Japan: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 34. India: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 35. South Korea: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 36. Australia: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 37. Rest of Asia-Pacific: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 38. Impact of COVID-19 Pandemic on Gastrointestinal Drugs market in Asia Pacific Countries
The List of Companies - Asia Pacific Gastrointestinal Drugs Market
- Johnson and Johnson Services, Inc.
- GlaxoSmithKline plc
- Celltrion Healthcare Co., Ltd.
- AstraZeneca
- Takeda Pharmaceutical Company Limited
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Asia Pacific Gastrointestinal Drugs Market
Nov 2020
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Nov 2020
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Nov 2020
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Nov 2020
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Nov 2020
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Nov 2020
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Nov 2020
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Nov 2020
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)